Bifidobacterium infantis strain YLGB‐1496 possesses excellent antioxidant and skin barrier‐enhancing efficacy in vitro

Atopic dermatitis (AD) is a recurring allergic skin disease that has a high incidence. Orally applied Bifidobacteria ameliorate signs of irritated skin and enhance the skin barrier. The present study investigated the safety and efficacy of a topically used cell‐free culture supernatant (CFS) from a...

Full description

Saved in:
Bibliographic Details
Published inExperimental dermatology Vol. 31; no. 7; pp. 1089 - 1094
Main Authors Ma, Xue, Pan, Yao, Zhao, Wen, Sun, Peiwen, Zhao, Jinfeng, Yan, Shiyu, Wang, Rui, Han, Yuqing, Liu, Wei‐Hsien, Tan, Shengjie, Hung, Wei‐Lian
Format Journal Article
LanguageEnglish
Published Denmark Wiley Subscription Services, Inc 01.07.2022
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Atopic dermatitis (AD) is a recurring allergic skin disease that has a high incidence. Orally applied Bifidobacteria ameliorate signs of irritated skin and enhance the skin barrier. The present study investigated the safety and efficacy of a topically used cell‐free culture supernatant (CFS) from a Bifidobacterium infantis strain using in vitro evaluation methods. The results showed that CFS had strong free radical scavenging activity on DPPH, ABTS, ·OH and O2‐radicals. CFS treatment fundamentally reduced the intracellular reactive oxygen species (ROS) and malondialdehyde (MDA) contents and improved the activities of antioxidant enzymes (CAT, SOD and GSH‐Px) in H2O2‐treated HaCaT cells. Notably, the upregulation of skin physical barrier gene (FLG, LOR, IVL, AQP3 and TGM1) expression and skin antimicrobial peptide gene (CAMP, hBD‐2 and hBD‐3) expression by CFS might contribute to skin barrier resistance. CFS was non‐irritating to the skin and eyes. CFS from the Bifidobacterium infantis strain had strong antioxidant properties on the skin and strengthened skin barrier function, and it was safe for topical use.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0906-6705
1600-0625
DOI:10.1111/exd.14583